Infusion fluids contain harmful glucose degradation products

Intensive Care Medicine

Volumn 36, Issue 7, 2010, Pages 1213-1220

  Bryland, Anna ^a   Broman, Marcus ^b   Erixon, Martin ^a   Klarin, Bengt ^b   Lindén, Torbjörn ^c   Friberg, Hans ^b   Wieslander, Anders ^c   Kjellstrand, Per ^c   Ronco, Claudio ^d   Carlsson, Ola ^c   Godaly, Gabriela ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Gambro AB   (Sweden)

^d SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Advanced glycation end products; Cell survival; Glucose; Infusion fluids; Innate defense; Neutrophils; Toxicity

Indexed keywords

3 DEOXYGLUCOSONE; 3,4 DIDEOXYGLUCOSONE 3 ENE; 5 HYDROXYMETHYLFURFURAL; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; GLUCOSE DEGRADATION PRODUCT; INFUSION FLUID; INTERLEUKIN 6; INTERLEUKIN 8; SODIUM CHLORIDE; UNCLASSIFIED DRUG; GLUCOSE; ISOTONIC SOLUTION; SOLUTION AND SOLUBILITY;

ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD; BLOOD LEVEL; CELL FUNCTION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FEMALE; GLUCOSE INFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUTROPHIL; CHEMISTRY; COMPARATIVE STUDY; DRUG CONTAMINATION; DRUG EFFECTS; FLUID THERAPY; INSTRUMENT STERILIZATION; INTENSIVE CARE; METABOLISM; PROCEDURES; SOLUTION AND SOLUBILITY;

CRITICAL CARE; DRUG CONTAMINATION; FEMALE; FLUID THERAPY; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; ISOTONIC SOLUTIONS; MALE; NEUTROPHILS; PHARMACEUTICAL SOLUTIONS; SALINE SOLUTION, HYPERTONIC; STERILIZATION;

EID: 77954383995     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-010-1873-x     Document Type: Article

References (40)

1. G Iapichino M Albicini M Umbrello F Sacconi I Fermo R Pavlovich R Paroni G Bellani G Mistraletti M Cugno A Pesenti L Gattinoni 2008 Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients Intensive Care Med 34 1843 1850 10.1007/s00134-008-1158-9 18504551
2. M Michalia M Kompoti A Koutsikou A Paridou P Giannopoulou E Trikka-Graphakos P Clouva-Molyvdas 2009 Diabetes mellitus is an independent risk factor for ICU-acquired bloodstream infections Intensive Care Med 35 448 454 10.1007/s00134-008-1288-0 1:STN:280:DC%2BD1M7ktFKqsA%3D%3D 18807006
3. JC Preiser P Devos S Ruiz-Santana C Melot D Annane J Groeneveld G Iapichino X Leverve G Nitenberg P Singer J Wernerman M Joannidis A Stecher R Chiolero 2009 A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study Intensive Care Med 35 1738 1748 10.1007/s00134-009-1585-2 1:CAS:528:DC%2BD1MXhtFOiu7fE 19636533
4. S Finfer DR Chittock SY Su D Blair D Foster V Dhingra R Bellomo D Cook P Dodek WR Henderson PC Hebert S Heritier DK Heyland C McArthur E McDonald I Mitchell JA Myburgh R Norton J Potter BG Robinson JJ Ronco 2009 Intensive versus conventional glucose control in critically ill patients N Engl J Med 360 1283 1297 10.1056/NEJMoa0810625 19318384
5. AP Wieslander MK Nordin PT Kjellstrand UC Boberg 1991 Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929 Kidney Int 40 77 79 10.1038/ki.1991.182 1:CAS:528:DyaK3MXlsVaisL8%3D 1921158
6. T Linden G Forsback R Deppisch T Henle A Wieslander 1998 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis Perit Dial Int 18 290 293 1:STN:280:DyaK1czislShtA%3D%3D 9663893
7. T Linden A Cohen R Deppisch P Kjellstrand A Wieslander 2002 3, 4-Dideoxyglucosone-3-ene (3, 4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis Kidney Int 62 697 703 10.1046/j.1523-1755.2002. 00490.x 1:CAS:528:DC%2BD38Xmt1GlsLg%3D 12110035
8. CC Conaway J Whysner LK Verna GM Williams 1996 Formaldehyde mechanistic data and risk assessment: endogenous protection from DNA adduct formation Pharmacol Ther 71 29 55 10.1016/0163-7258(96)00061-7 1:CAS:528: DyaK28XmtFenu7s%3D 8910948
9. LW Morgan A Wieslander M Davies T Horiuchi Y Ohta MJ Beavis KJ Craig JD Williams N Topley 2003 Glucose degradation products (GDP) retard remesothelialization independently of d-glucose concentration Kidney Int 64 1854 1866 10.1046/j.1523-1755.2003.00265.x 1:CAS:528:DC%2BD3sXpsVCrtL8%3D 14531821
10. P Justo AB Sanz J Egido A Ortiz 2005 3, 4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells Diabetes 54 2424 2429 10.2337/diabetes.54.8.2424 1:CAS:528:DC%2BD2MXnt1ynt7w%3D 16046310
11. MP Catalan B Santamaria A Reyero A Ortiz J Egido A Ortiz 2005 3, 4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis Kidney Int 68 1303 1311 10.1111/j.1523-1755.2005.00528.x 1:CAS:528:DC%2BD2MXhtVCjt7rJ 16105065
12. M Erixon A Wieslander T Linden O Carlsson JÅ Jönsson O Simonsen P Kjellstrand 2007 3, 4-DGE in peritoneal dialysis fluids cannot be found in plasma after infusion into the peritoneal cavity Perit Dial Int 28 277 278
13. M Zeier V Schwenger R Deppisch U Haug K Weigel U Bahner C Wanner H Schneider T Henle E Ritz 2003 Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63 298 305 10.1046/j.1523-1755.2003.00705.x 1:CAS:528: DC%2BD3sXmtV2gtg%3D%3D 12472796
14. PA Sarafidis A Whaley-Connell JR Sowers GL Bakris 2006 Cardiometabolic syndrome and chronic kidney disease: what is the link? J Cardiometab Syndr 1 58 65 10.1111/j.0197-3118.2006.05470.x 17675896
15. CL Lin FS Wang YR Kuo YT Huang HC Huang YC Sun YH Kuo 2006 Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries Kidney Int 69 1593 1600 10.1038/sj.ki.5000329 1:CAS:528:DC%2BD28XjvF2ks7s%3D 16572112
16. Garcia Lopez E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P (2007) Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 27 suppl 2:S205-209
17. M Erixon A Wieslander T Linden O Carlsson G Forsback E Svensson JA Jonsson P Kjellstrand 2005 Take care in how you store your PD fluids: actual temperature determines the balance between reactive and non-reactive GDPs Perit Dial Int 25 583 590 1:CAS:528:DC%2BD28Xks1eksQ%3D%3D 16411526
18. M Erixon A Wieslander T Linden O Carlsson G Forsback E Svensson JA Jonsson P Kjellstrand 2006 How to avoid glucose degradation products in peritoneal dialysis fluids Perit Dial Int 26 490 497 1:CAS:528: DC%2BD28XptFWrs7s%3D 16881345
19. JD Williams N Topley KJ Craig RK Mackenzie M Pischetsrieder C Lage J Passlick-Deetjen 2004 The Euro-Balance trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane Kidney Int 66 408 418 10.1111/j.1523-1755.2004.00747.x 15200450
20. CP Schmitt D von Heyl S Rieger K Arbeiter KE Bonzel M Fischbach J Misselwitz AK Pieper F Schaefer 2007 Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content Nephrol Dial Transplant 22 2038 2044 10.1093/ndt/gfm148 1:CAS:528:DC%2BD2sXos12hs7c%3D 17420168
21. B Rippe O Simonsen O Heimburger A Christensson B Haraldsson G Stelin L Weiss FD Nielsen S Bro M Friedberg A Wieslander 2001 Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products Kidney Int 59 348 357 10.1046/j.1523-1755.2001.00497.x 1:CAS:528:DC%2BD3MXot1yltQ%3D%3D 11135090
22. J Montenegro R Saracho I Gallardo I Martinez R Munoz N Quintanilla 2007 Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis Nephrol Dial Transplant 22 1703 1708 10.1093/ndt/gfl848 1:CAS:528:DC%2BD2sXot1SgsLo%3D 17405794
23. HY Lee HY Choi HC Park BJ Seo JY Do SR Yun HY Song YH Kim YL Kim DJ Kim YS Kim MJ Kim SK Shin 2006 Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome Nephrol Dial Transplant 21 2893 2899 10.1093/ndt/gfl393 1:CAS:528: DC%2BD28XhtVWltrbP 16957012
24. AP Wieslander AH Andren C Nilsson-Thorell N Muscalu PT Kjellstrand B Rippe 1995 Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 15 348 352 1:STN:280:DyaK283ktFSquw%3D%3D 8785233
25. RJ Ulbricht SJ Northup JA Thomas 1984 A review of 5-hydroxymethylfurfural (HMF) in parenteral solutions Fundam Appl Toxicol 4 843 853 10.1016/0272-0590(84)90106-4 1:CAS:528:DyaL2MXjtF2ktA%3D%3D 6391997
26. H Kusunoki S Miyata T Ohara BF Liu A Uriuhara H Kojima K Suzuki H Miyazaki Y Yamashita K Inaba M Kasuga 2003 Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy Diabetes Care 26 1889 1894 10.2337/diacare.26.6.1889 1:CAS:528:DC%2BD3sXkslKrtb0%3D 12766129
27. PM Humpert IK Lukic SR Thorpe S Hofer EM Awad M Andrassy EK Deemer M Kasper E Schleicher M Schwaninger MA Weigand PP Nawroth A Bierhaus 2009 AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis J Leukoc Biol 86 589 597 10.1189/jlb.1008646 1:CAS:528:DC%2BD1MXhtFahtb7I 19401390
28. S Agalou N Ahmed PJ Thornalley A Dawnay 2005 Advanced glycation end product free adducts are cleared by dialysis Ann NY Acad Sci 1043 734 739 10.1196/annals.1333.085 1:CAS:528:DC%2BD2MXpvVKqu74%3D 16037300
29. S Agalou N Ahmed R Babaei-Jadidi A Dawnay PJ Thornalley 2005 Profound mishandling of protein glycation degradation products in uremia and dialysis J Am Soc Nephrol 16 1471 1485 10.1681/ASN.2004080635 1:CAS:528: DC%2BD2MXksF2gsb4%3D 15800128
30. A Simm J Wagner T Gursinsky N Nass I Friedrich R Schinzel E Czeslik RE Silber RJ Scheubel 2007 Advanced glycation endproducts: a biomarker for age as an outcome predictor after cardiac surgery? Exp Gerontol 42 668 675 10.1016/j.exger.2007.03.006 1:CAS:528:DC%2BD2sXlsF2ht7c%3D 17482402
31. S Franke A Muller M Sommer M Busch R Kientsch-Engel G Stein 2003 Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end-products (AGEs) in patients after renal transplantation Clin Nephrol 59 88 97 1:CAS:528:DC%2BD3sXivVGqt74%3D 12608551
32. TR Brown B Su KA Brown MA Schwartz AM Tobia F Kappler 2003 Modulation of in vivo 3-deoxyglucosone levels Biochem Soc Trans 31 1433 1437 10.1042/BST0311433 1:CAS:528:DC%2BD3sXps12jtLg%3D 14641082
33. S Costa P Coelho C Costa S Silva O Mayan LS Santos J Gaspar JP Teixeira 2008 Genotoxic damage in pathology anatomy laboratory workers exposed to formaldehyde Toxicology 252 40 48 10.1016/j.tox.2008.07.056 1:CAS:528: DC%2BD1cXht1ens7fM 18721846
34. A Zwart RA Woutersen JW Wilmer BJ Spit VJ Feron 1988 Cytotoxic and adaptive effects in rat nasal epithelium after 3-day and 13-week exposure to low concentrations of formaldehyde vapour Toxicology 51 87 99 10.1016/0300-483X(88) 90083-2 1:CAS:528:DyaL1cXls1GhsbY%3D 3413803
35. ME Williams 2006 New potential agents in treating diabetic kidney disease: the fourth act Drugs 66 2287 2298 10.2165/00003495-200666180-00002 1:CAS:528:DC%2BD2sXhs1aktLs%3D 17181372
36. SV Chetyrkin W Zhang BG Hudson AS Serianni PA Voziyan 2008 Pyridoxamine protects proteins from functional damage by 3-deoxyglucosone: mechanism of action of pyridoxamine Biochemistry 47 997 1006 10.1021/bi701190s 1:CAS:528:DC%2BD2sXhsVOntb%2FM 18161948
37. S Nakamura H Li A Adijiang M Pischetsrieder T Niwa 2007 Pyridoxal phosphate prevents progression of diabetic nephropathy Nephrol Dial Transplant 22 2165 2174 10.1093/ndt/gfm166 1:CAS:528:DC%2BD2sXos1ylt7Y%3D 17449494
38. NL Alderson ME Chachich NN Youssef RJ Beattie M Nachtigal SR Thorpe JW Baynes 2003 The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats Kidney Int 63 2123 2133 10.1046/j.1523-1755.2003.00027.x 1:CAS:528:DC%2BD3sXkvVyiu7o%3D 12753299
39. EA Muellenbach CJ Diehl MK Teachey KA Lindborg TL Archuleta NB Harrell G Andersen V Somoza O Hasselwander M Matuschek EJ Henriksen 2008 Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat Metabolism 57 1465 1472 10.1016/j.metabol.2008.05.018 1:CAS:528:DC%2BD1cXhtFekt7rM 18803954
40. LM Berstein DA Vasilyev TE Poroshina IG Kovalenko 2006 Glucose-induced effects and joker function of glucose: endocrine or genotoxic prevalence? Horm Metab Res 38 650 655 10.1055/s-2006-954589 1:CAS:528:DC%2BD2sXot1Q%3D 17075773